The company announced the pricing of a public stock offering.
News & Analysis: MATINAS BIOPHARMA
The small-cap pharma sank on an update from its top competitor.
Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.
Matinas BioPharma's lead candidate failed to hit the mark in a mid-stage trial.